Ashish Mandelia Mersana Therapeutics, Inc. (MRSN) insider trading activity

Ashish Mandelia is VP, Chief Accounting Officer of Mersana Therapeutics, Inc.. Currently has a direct ownership of 0 shares of MRSN, which is worth approximately $0. The most recent transaction as insider was on Jan 06, 2026, when has been sold 2,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Ashish Mandelia Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	SELL Disposition due to a tender of shares in a change of control transaction	-	2,300 Reduced 100.0%	0 Common Stock
Jan 16 2025	SELL Open market or private sale	$2,061 $0.58 p/Share	3,554 Reduced 5.82%	57,519 Common Stock
Jan 15 2025	SELL Open market or private sale	$1,128 $0.63 p/Share	1,791 Reduced 3.31%	52,388 Common Stock
Jan 15 2025	BUY Exercise of conversion of derivative security	-	8,685 Added 12.45%	61,073 Common Stock
Jan 14 2025	SELL Open market or private sale	$664 $0.66 p/Share	1,007 Reduced 2.0%	49,396 Common Stock
Jan 14 2025	BUY Exercise of conversion of derivative security	-	4,783 Added 8.11%	54,179 Common Stock
Jan 13 2025	BUY Exercise of conversion of derivative security	-	2,646 Added 4.99%	50,403 Common Stock

Oct 03 2024	SELL Open market or private sale	$6,587 $1.96 p/Share	3,361 Reduced 6.57%	47,757 Common Stock
Oct 02 2024	SELL Open market or private sale	$9,710 $2.0 p/Share	4,855 Reduced 8.67%	51,118 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	-	30,000 Added 34.89%	55,973 Common Stock
Jan 16 2024	SELL Open market or private sale	$13,617 $2.71 p/Share	5,025 Reduced 17.72%	23,328 Common Stock
Jan 15 2024	BUY Exercise of conversion of derivative security	-	5,352 Added 15.88%	28,353 Common Stock
Jan 14 2024	BUY Exercise of conversion of derivative security	-	4,783 Added 17.21%	23,001 Common Stock
Jan 13 2024	BUY Exercise of conversion of derivative security	-	2,645 Added 12.68%	18,218 Common Stock
Jan 17 2023	SELL Open market or private sale	$20,520 $5.74 p/Share	3,575 Reduced 20.79%	13,619 Common Stock
Jan 15 2023	BUY Exercise of conversion of derivative security	-	5,352 Added 23.74%	17,194 Common Stock
Jan 14 2023	BUY Exercise of conversion of derivative security	-	4,784 Added 28.77%	11,842 Common Stock
Jan 18 2022	SELL Open market or private sale	$11,733 $5.92 p/Share	1,982 Reduced 37.03%	3,371 Common Stock
Jan 14 2022	BUY Exercise of conversion of derivative security	-	5,353 Added 50.0%	5,353 Common Stock
Jul 01 2021	SELL Open market or private sale	$12,811 $13.6 p/Share	942 Reduced 100.0%	0 Common Stock
Jan 19 2021	SELL Open market or private sale	$11,598 $21.28 p/Share	545 Reduced 100.0%	0 Common Stock
Jan 15 2021	SELL Payment of exercise price or tax liability	$6,095 $21.09 p/Share	289 Reduced 34.65%	545 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	-	834 Added 50.0%	834 Common Stock
Jan 04 2021	SELL Open market or private sale	$6,610 $26.76 p/Share	247 Reduced 100.0%	0 Common Stock

Ashish Mandelia

VP, Chief Accounting Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRSN shares.

Notify only if

Value

Insider Trading

Get notified when an Mersana Therapeutics, Inc. insider buys or sells MRSN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Mersana Therapeutics, Inc.

Track Activities on MRSN

Account